Lytenava (bevacizumab-vikg)

Neovascular age-related macular degeneration

Manufacturer: Outlook Therapeutics
Regulatory submission: BLA approved July 2026
Launch: Anticipated before the end of 2026
Last updated: September 28, 2026

Section

Product information and disease description Place of product in therapy

Approaches to treatment

43 evidence topics · 20 sources

Current treatment options and standard of care20 evidence topics · 13 sources
Place in treatment, anticipated use, and care setting6 evidence topics · 3 sources
Heterogeneity of treatment effect4 evidence topics · 3 sources
Care management intervention strategies4 evidence topics · 4 sources
Other product development or post-marketing obligations required by the FDA3 evidence topics · 1 source
Ongoing post-approval monitoring3 evidence topics · 1 source
Expected outcomes of therapy3 evidence topics · 2 sources